Why is it still drug discovery?
Explore luck and judgement in drug discovery
M. D. Segall, Eur. Biopharma. Rev., 2008
Matthew Segall (while still in the ADMET Division, BioFocus DPI), explored the balance between luck and judgement in drug discovery. As Matt put it “The vision of an in silico design process for drug molecules is certainly attractive, so why has this goal yet to be realised, despite an enormous effort over the past 10 years?”
Estimates for average costs and durations vary, but a reasonable approximation puts the typical duration for bringing a drug to market at 12-15 years (1). The average cost is at over $800 million (2). The reason for this is that the process is dominated by failure. There is a high attrition rate of compounds and projects, even in the later and most expensive clinical phases. Therefore, the majority of the cost is associated with compounds and projects that never result in a marketed drug.
Find out more
You can download a copy of this article on luck and judgement in drug discovery as a PDF file via the button below. Alternatively, visit the journal webpage.
INTERESTED IN DRUG DEVELOPMENT?
With its comprehensive suite of integrated software, StarDrop™ delivers best-in-class in silico technologies within a highly visual and user-friendly interface. StarDrop™ enables a seamless flow from the latest data through predictive modelling to decision-making regarding the next round of synthesis and research. This improves the speed, efficiency, and productivity of the drug optimisation and discovery process.